DE602004018175D1 - Geschmacksmaskierte Formulierung von Clarithromycin - Google Patents

Geschmacksmaskierte Formulierung von Clarithromycin

Info

Publication number
DE602004018175D1
DE602004018175D1 DE602004018175T DE602004018175T DE602004018175D1 DE 602004018175 D1 DE602004018175 D1 DE 602004018175D1 DE 602004018175 T DE602004018175 T DE 602004018175T DE 602004018175 T DE602004018175 T DE 602004018175T DE 602004018175 D1 DE602004018175 D1 DE 602004018175D1
Authority
DE
Germany
Prior art keywords
clarithromycin
taste
masked formulation
masked
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004018175T
Other languages
English (en)
Inventor
Indranil Nandi
Mintong Guo
Chad Michael Gassert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/688,551 external-priority patent/US20050084540A1/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of DE602004018175D1 publication Critical patent/DE602004018175D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004018175T 2003-10-17 2004-10-15 Geschmacksmaskierte Formulierung von Clarithromycin Expired - Lifetime DE602004018175D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/688,551 US20050084540A1 (en) 2003-10-17 2003-10-17 Taste masking antibiotic composition
US10/768,562 US8168228B2 (en) 2003-10-17 2004-01-30 Antibiotic clarithromycin micropellet compositions
PCT/EP2004/011653 WO2005039536A1 (en) 2003-10-17 2004-10-15 Antibiotic compositions

Publications (1)

Publication Number Publication Date
DE602004018175D1 true DE602004018175D1 (de) 2009-01-15

Family

ID=34527177

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018175T Expired - Lifetime DE602004018175D1 (de) 2003-10-17 2004-10-15 Geschmacksmaskierte Formulierung von Clarithromycin

Country Status (19)

Country Link
US (2) US8168228B2 (de)
EP (1) EP1680088B1 (de)
JP (1) JP2007508351A (de)
CN (1) CN1893927A (de)
AR (1) AR046113A1 (de)
AT (1) ATE415948T1 (de)
AU (1) AU2004283463B2 (de)
BR (1) BRPI0415450A (de)
CA (1) CA2542238A1 (de)
DE (1) DE602004018175D1 (de)
DK (1) DK1680088T3 (de)
ES (1) ES2317061T3 (de)
HR (1) HRP20090124T3 (de)
PE (1) PE20050441A1 (de)
PL (1) PL1680088T3 (de)
PT (1) PT1680088E (de)
RU (1) RU2376980C2 (de)
SI (1) SI1680088T1 (de)
WO (1) WO2005039536A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN102665422B (zh) * 2009-12-23 2015-01-28 疫苗基因集团 通过口服施用重组乳酸乳球菌微型胶囊的免疫保护方法
US20130034609A1 (en) * 2010-02-09 2013-02-07 Agency For Science, Technology And Research Smart polymers functionalized hollow silica vesicles
EP2386297A1 (de) * 2010-04-28 2011-11-16 Roquette Frères Unverdauliches Polymer: Filmüberzüge auf Basis von acetylierter Stärke für Colon-Targeting
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
BR112013027484A8 (pt) * 2011-06-17 2022-07-05 Evonik Roehm Gmbh Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
CN107960589A (zh) * 2016-10-20 2018-04-27 湖南晶天科技实业有限公司 一种抗菌添加剂壳寡糖醛席夫碱和应用
CN107960533A (zh) * 2016-10-20 2018-04-27 湖南晶天科技实业有限公司 一种氨基酸醛席夫碱饲料添加剂以及一种饲料
CN110075085A (zh) * 2019-05-17 2019-08-02 南京望知星医药科技有限公司 一种罗红霉素微囊及其制备方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
CN113777329B (zh) * 2021-09-16 2023-07-18 何秋富 一种视黄醇结合蛋白测定试剂盒及其制备方法
WO2024043260A1 (en) * 2022-08-24 2024-02-29 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising centanafadine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3099711A (en) * 1961-06-02 1963-07-30 Data Presentations Inc Printing device
EP0188040B1 (de) 1985-01-11 1991-08-14 Abbott Laboratories Limited Feste Zubereitung mit langsamer Freisetzung
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JPH05255120A (ja) * 1992-03-12 1993-10-05 Taisho Pharmaceut Co Ltd 苦み隠蔽製剤
TW271400B (de) 1992-07-30 1996-03-01 Pfizer
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
SE9700885D0 (sv) * 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
US6010718A (en) 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
JP2000103730A (ja) * 1998-07-31 2000-04-11 Otsuka Pharmaceut Co Ltd 服用感が改善された医薬組成物
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
IN191239B (de) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6451345B1 (en) 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
KR20030011797A (ko) 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
IN192748B (de) 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
JP3211824B1 (ja) * 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
ES2195727B1 (es) 2001-07-05 2005-03-01 Ercros Industrial, S.A. Un procedimiento para la obtencion de claritromicina.
WO2003017981A1 (en) 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
WO2003020242A1 (en) 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US6642276B2 (en) 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
KR20050009983A (ko) * 2002-03-22 2005-01-26 시락 아게 트라마돌의 서방성 제제
EP1578350B1 (de) * 2002-03-26 2009-05-27 Euro-Celtique S.A. Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
BR0308990A (pt) 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação
CA2481271A1 (en) 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Clarithromycin formulations having improved bioavailability
JP4743684B2 (ja) * 2002-05-22 2011-08-10 塩野義製薬株式会社 難水溶性薬物の溶出性を改善する方法

Also Published As

Publication number Publication date
EP1680088A1 (de) 2006-07-19
US20070134344A1 (en) 2007-06-14
WO2005039536A1 (en) 2005-05-06
SI1680088T1 (sl) 2009-08-31
AR046113A1 (es) 2005-11-23
RU2376980C2 (ru) 2009-12-27
ES2317061T3 (es) 2009-04-16
PL1680088T3 (pl) 2009-06-30
DK1680088T3 (da) 2009-03-23
BRPI0415450A (pt) 2006-12-19
ATE415948T1 (de) 2008-12-15
AU2004283463B2 (en) 2007-12-20
JP2007508351A (ja) 2007-04-05
CN1893927A (zh) 2007-01-10
CA2542238A1 (en) 2005-05-06
PE20050441A1 (es) 2005-08-02
HRP20090124T3 (en) 2009-04-30
AU2004283463A1 (en) 2005-05-06
US8168228B2 (en) 2012-05-01
US20050084541A1 (en) 2005-04-21
PT1680088E (pt) 2009-01-30
RU2006116622A (ru) 2007-12-10
EP1680088B1 (de) 2008-12-03

Similar Documents

Publication Publication Date Title
DK3384931T3 (da) Superfin formoterolformulering
NO20033384L (no) Farmasoytisk formulering
DE602005012267D1 (de) N von geräten
NO20033785L (no) Farmasöytisk formulering
MX266708B (es) Formulaciones de microparticulas de pantoprazol.
IS8309A (is) Lyfjablöndur
NO20040125L (no) Enterale formuleringer
ATE382261T1 (de) Flüssige formulierung
FI20030261A (fi) Iskulaite
NO20044916L (no) Preparater av sulfinylacetamid
NO20035627D0 (no) Farmasöytisk formulering
ATE415948T1 (de) Geschmacksmaskierte formulierung von clarithromycin
NO20043576L (no) Pharmaceutical formulation comprising melatonin
DE60324491D1 (de) Kultivator
DE60315984D1 (de) Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
DE502004011589D1 (de) Silylierte carboxamide
DE602004013599D1 (de) Herstellung von somatostatinpeptiden
TR200400375T3 (tr) Taksanlarin sabit araliklarla dozlanmasi
DE60234539D1 (de) Geschmacksmaskierte orale zubereitung von telithromycin
DE50309824D1 (de) Bodenbearbeitungsgerät
DE602004016680D1 (de) N von tests
DE60323088D1 (de) Leberschützende wirkung der 10-o-p-hydroxybenzoylaucubin
NO20041236L (no) Farmasoytisk formulering
ITTV20020100A1 (it) Struttura di dispositivo di regolazione particolarmente
SE0201660D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN